The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included.

Causes of metabolic acidosis in canine hemorrhagic shock: role of unmeasured ions.

Introduction: Metabolic acidosis during hemorrhagic shock is common and conventionally considered to be due to hyperlactatemia. There is increasing awareness, however, that other nonlactate, unmeasured anions contribute to this type of acidosis.

Methods: Eleven anesthetized dogs were hemorrhaged to a mean arterial pressure of 45 mm Hg and were kept at this level until a metabolic oxygen debt of 120 mLO2/kg body weight had evolved.

The concept of hemoglobin equivalency of perfluorochemical emulsions.

Perfluorochemical (PFC) emulsions have been in development as intravenous oxygen carriers for a number of years and many publications have dealt with their oxygen transport characteristics in both experimental models and in clinical trials. Though it has been stressed on numerous occasions that PFCs deliver oxygen to the tissues in very different ways to those by which Hemoglobin (Hb) releases oxygen (O2), no serious attempts have been made to correlate the oxygen delivery capacity of PFCs to those of Hb. This paper presents theoretical ways in which this can be done and demonstrates that a 2.

Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery.

Objective: To assess tolerance and preliminary efficacy of a perfluorocarbon emulsion (AF0144) used with acute normovolemic hemodilution to reduce allogeneic blood transfusion for patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).

Design: Controlled, single-blind, parallel-group phase II dose escalation trial.

Setting: Single-institution university medical center.